RE: LFT Sensitivity Comparison Study4 Jul 2021 16:22
The accuracy of Avacta’s test at the most pivotal point of infection offers a proper solution, unlike many of the alternatives.
Of course it’s going to sell in volume. Slightly frustrated about time to market but not worried in the slightest.